Menu

22nd Annual
San Diego Heart Failure Symposium for
Primary Care and Internal Medicine Physicians

New Strategies for Detection, Prevention and Treatment of Heart Failure
February 4 & 5, 2022
A Virtual Event from La Jolla, California

To access the Live Webcast and CME Surveys please login using your registration email address.


 

IMPORTANT CME CREDIT NOTICE

CME Certificates will be issued digitally after Speaker Evaluations and Overall Surveys are completed. Surveys are accessible after logging in with the email address you submitted during registration. Surveys will be available online starting the day of the symposium. You must complete the process by February 28, 2022 in order to receive your certificate. Certificates will be available online until August 1 and are printable directly from the website.

ACCREDITATION
PHYSICIANS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Continuing Education Company, Inc. and Complete Conference Management. Continuing Education Company, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Continuing Education Company, Inc. designates this live activity for a maximum of 9.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

NURSE PRACTITIONERS
AANPCB: The American Academy of Nurse Practitioners Certification Board (AANPCB) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Nurse Practitioners may receive a maximum of 9.5 hours of participation.

ANCC: According to ANCC Certification, the continuing education hours approved for AMA PRA Category 1 Credits™ meet the requirement of formally approved continuing education hours and may be used as such for ANCC Certification renewal.
FRIDAY SESSION II ACCREDITATION

In order to obtain CME credit for Session II, please complete this 5 question pre-test prior to the presentation:
https://akhinc.formstack.com/forms/20229pre

In order to receive your CME certificate, please complete the brief post-test & evaluation here:
https://www.akhcme.com/pah/

COURSE DESCRIPTION

This year’s 22nd Annual San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians will again be presented in a dynamic virtual format with Live Q&A on February 4-5, 2022. As in the past, the Symposium will provide a current review of the many new and emerging trends in managing patients with heart failure. The series of lectures have been designed to highlight the most important areas of progress. The goal is put these advances into context with other on-going management strategies. This year Day 1 of the Symposium will have Sessions on Strategies for Prevention with talks on treating hypertension, hyperlipidemia, diabetes and obesity and new approaches for treating Cardiac Hypertrophy, Amyloidosis and Other Infiltrative Diseases including talks on management of HFpEF, HFmrEF and HFimpEF, amyloidosis and pulmonary arterial hypertension. On Day 2, there will be a Session on Optimizing Treatment with talks focused on the role of ARNIs, SGLT2 inhibitors, newer drugs like omecamtiv mecarbil, vericiguat and finerenone as well as an important lecture on disparities in care. A Session on Advances in Management with introduce talks on biomarkers, remote monitoring, percutaneous treatments for valvular lesions. The final Session will include talks on anticoagulation, role of the wearable cardioverter/defibrillator, advances in pacemakers and defibrillators and devices for preventing stroke. Day 2 will finish with a Special Section in which a series of Fascinating Cases along with images will be presented. Interwoven with the lectures will be live panel and case discussions as well as extensive Q/A panels in order to allow registrants the opportunity to interact with the internationally renowned faculty that will presenting at the Symposium. Our goal is to continue the tradition of the preceding Symposia in providing cutting edge information about heart failure by experts in the field in a format that enhances adaption into clinical practice.

TARGET AUDIENCE

This course is designed for cardiologists, internists, primary care physicians, nurses, PA’s, PharmD’s and all other allied healthcare professionals with an interest in heart failure.

OBJECTIVES

At the conclusion of this activity, participants should be able to:

  1. Summarize current and emerging treatments available for preventing and treating heart failure and provide information to help in the selection of the most effective choices in individual patients.
  2. Review strategies for implementing medical and device therapies that will lead to improved outcomes in heart failure patients.
  3. Define how specific populations including minorities, women and the elderly respond to various approaches to treating risk factors and heart failure.

NEEDS ASSESSMENT

Over five million Americans (two percent of the U.S.) are living with heart failure (HF). An estimated 670,000 new cases of HF are diagnosed each year and this condition is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years) and is the number one cause of hospitalizations of the elderly in the U.S. HF is common, but unrecognized and often misdiagnosed. Recent data have shown that drugs and devices that have proven beneficial and are recommended in recent practice guidelines, (HFSA 2010 update of practice guidelines Lindelfield J et al J Cardiac Failure 2010:16; 475) are underutilized (Fonarow GC et al. Circulation 2010;122:585).

Recent information also suggests a significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF and a substantial gap in overall performance. In addition, according to a study analyzing the quality of health care in the U.S. on average, patients with heart failure received the recommended quality of care only 64% of the time (heart failure performance measurement set by the ACC/AHA 2010).

Despite important advances in treatment, patients with HF continue to experience unacceptably high rates of morbidity and mortality. This along with the enormous cost of caring for a growing number of HF patients has resulted in increased scrutiny of existing and emerging therapies.